CHICAGO, Sept 5 (Reuters) - Twice as many patients stopped taking Pfizer Inc.'s (PFE.N: Quote, Profile, Research) anti-blood clotting drug Fragmin due to death compared with those taking another anti-clotting treatment, U.S. regulatory staff said in a report released on Tuesday.
